Ensuring timely UK market access of ultra-orphan therapies – a roadmap for maximising commercial opportunity.

Having developed a high cost therapy to treat a rare disease, our client needed to establish an appropriate market access strategy in preparation for the UK launch of their asset.

Eradigm conducted an in-depth assessment of therapies that had previously been successfully approved by NICE’s High Specialised Technologies Unit. This enabled us to deliver a robust and informed strategy for ensuring timely market access, without conceding a significant discount and enabled our client to maximise their commercial opportunity.